Vedanta Biosciences
Develops microbiome-based oral therapies for prevention of recurrent C. difficile infection
$60MGrowth
Role not disclosedLoading investors…
Activity from announced rounds
Develops microbiome-based oral therapies for prevention of recurrent C. difficile infection
Developing a next-generation pertussis vaccine candidate BPZE1